Deadline: 31 May 2020
Sanofi Genzyme is offering research grants to ten innovative projects designed to improve the lives of people with immune-mediated diseases (the “Type 2 Innovation Grant”).
The objective of the Type 2 Innovation Grant is to support independent, novel and innovative research projects investigating Type 2 immune-mediated diseases, such as atopic dermatitis, asthma or chronic rhinosinusitis with nasal polyps (CRSwNP) (or “Type 2 immune-mediate diseases with relevance in clinical practices”).
Qualifying research grant applicants will be requested to select between two disease areas, Dermatology or Respiratory and, in this latter category, applicants must also choose if their proposal is related to Pulmonology or Rhinology. The applications will then be evaluated against predefined criteria by two independent panels of international experts, one per disease area.
Your research projects must be designed to advance knowledge in the field of Type 2 immune-mediated diseases, including atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyps, with relevance to clinical practice. Research projects with clear potential to advance patient care outcomes or reduce individual disease burden will be prioritized.
What qualifies as a Type 2 immune-mediated disease?
- Your research projects must have a direct relevance to the mechanism of Type 2 immunity and should therefore include conditions such as atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyps.
- You will be requested to select between two disease areas when applying – Dermatology or Respiratory, in this latter case you must choose if your proposal is related to Pulmonology or Rhinology.
Funding Information
- Sanofi Genzyme will financially support each winning research project with a research grant up to EUR 80,000.
- The exact amount of the research grant will be decided by Sanofi Genzyme taking into account the budget breakdown submitted by the applicant in support of the research grant application.
- The research grant period is 12 months from the moment of payment of the research grant.
Eligibility Criteria
- Only not-for-profit organizations can apply for a research grant. The institutions of their expert panel members are excluded from participation in the Type 2 Innovation Grant.
- Applicants must be established in the European Economic Area (EEA) or the UK. As of February 2020, the EEA comprises of the following countries: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lichtenstein, Lithuania, Luxembourg, Malta, The Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and Switzerland
- Submissions from applicants from countries not listed above cannot be accepted
- Applicants must be a not-for-profit organization, duly incorporated and registered in a country belonging to the list of countries mentioned in the previous paragraph
- Research projects related to investigational or marketed medicinal product, and to diagnostic tests on humans are not accepted
- The research grant will not, under any circumstances, be paid to an individual healthcare professional
For more information, visit https://www.type2innovationgrant.com/res/p/researchgrant/